Loading
A phase 2 trial of SHR-A2102, Retlirafusp alfa in non-small-cell lung cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.
Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects is a phase 2 interventional study registered as NCT07175220 by Jiangsu HengRui Medicine Co., Ltd., with 200 participants planned, started 2025-10-09 and due to reach its primary completion in 2028-10. Interventions recorded: SHR2554; SHR-A2102, SHR2554; Adabelimumab, SHR2554; SHR-1701. Conditions listed: Locally Advanced or Metastatic Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Retlirafusp alfa, Immune exclusion, Jiangsu Hengrui Pharmaceuticals.
Shares Retlirafusp alfa, Immune exclusion, Jiangsu Hengrui Pharmaceuticals.
Shares SHR-A2102, Jiangsu Hengrui Pharmaceuticals.
Shares Retlirafusp alfa, Immune exclusion.
Shares SHR-A2102, Jiangsu Hengrui Pharmaceuticals, Non-small-cell lung cancer.
Shares SHR-A2102, Jiangsu Hengrui Pharmaceuticals.
Shares SHR-A2102, Jiangsu Hengrui Pharmaceuticals, Non-small-cell lung cancer.
Shares Retlirafusp alfa, Immune exclusion.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/